Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Ovarian Cancer Claim For Antisoma Oncologic On Back Burner

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Disappointing Phase II results for ASA404, which is licensed to Novartis, will not impact research in lung, prostate cancer.

You may also be interested in...



Novartis Launches Phase III Trial For NSCLC Candidate

Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.

Novartis Launches Phase III Trial For NSCLC Candidate

Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.

Oxigene Reports Positive Data For Zybrestat In Platinum-Resistant Ovarian Cancer

Novel vascular disrupting agent is also in studies for anaplastic thyroid cancer and macular degeneration.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS066307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By